Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | AKT2 | P31751 | 2/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lofemizole SCHEMBL44549 | 0.98 | SMN1; SMN2 (0.47) | ADORA3SMN1; SMN2ADORA2AADORA1AKT2 | |
| SCHEMBL22434856 | 0.83 | ADORA3 (0.50) | ADORA3SMN1; SMN2ADORA2AADORA1KDM4E | |
| SCHEMBL21428970 | 0.80 | MAPK14 (0.54) | SMN1; SMN2KDM4ECYP3A4MAPTERBB2 | |
| SCHEMBL4866745 | 0.79 | PIK3CD (0.43) | KDM4ECYP3A4CCNB2CDK1CCNB1 | |
| SCHEMBL8002000 | 0.79 | KDM4E (0.61) | ADORA3SMN1; SMN2ADORA2AADORA1AKT2 | |
| SCHEMBL7295129 | 0.78 | MAPK14 (0.51) | KDM4ECYP3A4MAPTCCNB2CDK1 | |
| SCHEMBL4075858 | 0.78 | KDM4E (0.64) | ADORA3ADORA2AADORA1AKT2PRKACA | |
| SCHEMBL5717900 | 0.76 | KIF11 (0.42) | — | |
| SCHEMBL15444885 | 0.74 | HSD11B1 (0.46) | KDM4EMAPT | |
| SCHEMBL18612329 | 0.74 | NISCH (0.41) | SMN1; SMN2AKT2PRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3279663-B1 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-07-28 | — | — | EP | claimed |
| EP-2001496-B1 | USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES | BRIGHAM & WOMENS HOSPITAL INC (US) | 2017-05-31 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-4499104-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, ANTICONVULSANT AGENTS | FARMATIS S.R.L. (IT) | 1985-02-12 | — | — | US | claimed |
| US-20260061093-A1 | LIPID ANALOGS, LIPOSOMES COMPRISING SAME AND USES THEREOF | LIPOSPHERE LTD. (IL) | 2026-03-05 | — | — | US | disclosed |
| US-20250304667-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-3693381-B1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LTD (AU) | 2025-09-03 | — | — | EP | disclosed |
| EP-4580693-A1 | LIPID ANALOGS, LIPOSOMES COMPRISING SAME AND USES THEREOF | Liposphere Ltd. (IL) | 2025-07-09 | — | — | EP | disclosed |
| EP-0136893-A2 | Benzo[a]phenothiazines and hydro-derivatives and pharmaceutical compositions containing them | MERCK FROSST CANADA INC. (CA) | 1985-04-10 | — | — | EP | disclosed |
| US-4499104-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, ANTICONVULSANT AGENTS | FARMATIS S.R.L. (IT) | 1985-02-12 | — | — | US | disclosed |
| US-4499104-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, ANTICONVULSANT AGENTS | FARMATIS S.R.L. (IT) | 1985-02-12 | — | — | US | disclosed |
| EP-0123541-A1 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1984-10-31 | — | — | EP | disclosed |
| EP-0123543-A1 | Leukotriene antagonists, their production and use and compositions containing them | MERCK FROSST CANADA INC. (CA) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061093-A1 | LIPID ANALOGS, LIPOSOMES COMPRISING SAME AND USES THEREOF | PHOSPHO1, SGMS1, SGMS2 | ADORA3 3429/4885SMN1; SMN2 4231/4885ADORA2A 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.